期刊
IMMUNOTHERAPY
卷 12, 期 17, 页码 1213-1219出版社
FUTURE MEDICINE LTD
DOI: 10.2217/imt-2020-0108
关键词
anti-PD-1; checkpoint inhibitors; fracture; immunotherapy; melanoma; nivolumab; osteonecrosis
类别
资金
- Roche/Genentech
- GSK
- Astrazeneca
- Sanofi-Aventis
- Merck
- Myriad
- Oncothyreon
- NIH/NCI [2T32CA009666-25]
- Dr Miriam and Sheldon G Adelson Medical Research Foundation
- AIM at Melanoma Foundation
Recognizing rare but clinically significant toxicity of immunotherapy is critical. Here we describe the first detailed case of severe osteonecrosis of the jaw due to anti-PD-1. A 75-year-old man with metastatic melanoma, with no prior radiation or treatment with bone-targeting agents, experienced jaw pain 1 week after his first dose of nivolumab. Imaging studies were negative, and treatment was resumed after pain was controlled. 4 months later, the patient experienced acute exacerbation of pain and malocclusion of the jaw. Imaging showed bilateral fractures of the angle of mandible with extensive disruption of the normal trabecular architecture, requiring total mandibulectomy. The patient's metastatic melanoma responded to treatment and remains controlled >20 months after treatment cessation without further therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据